The tumor-specific MMAE prodrug nanoparticles, FRRG-MMAE, constructed with cathepsin B-specific cleavable FRRG (Phe-Arg-Arg-Gly) peptide and MMAE, were designed to reduce the severe MMAE-related toxicity and to enhance their antitumor efficacy. Here, CTSB is linked to neoplasm.